Figure 4
miR-301a deficiency inhibits the severity of colitis. (a) Expression of miR-301a during DSS-induced acute colitis. (b) Body weight loss during DSS-induced colitis in WT (n=10) and miR-301a−/− (n=10) mice. (c) Overview of colon shortening in treated mice. (d) Colon length of WT (n=10) and miR-301a−/− (n=10) mice with and without DSS treatment. (e) Colitis severity score 12 days after DSS-treated WT (n=10) and miR-301a−/− (n=10) mice. (f) Representative histological sections of mouse colon stained with hematoxylin and eosin (H&E; n=10 per group). Scale bars, 200 μm. (g) Cell proliferation during DSS-induced colitis in WT (n=10) and miR-301a−/− (n=10) mice as determined by Ki67 staining. Scale bars, 50 μm. (h) Ki67-positive cell counts in colon sections (n=10 per group). Values are means±s.d. **P⩽0.01 indicates the significance of the differences between the indicated groups.
